This trial is evaluating whether Treatment will improve 1 primary outcome and 6 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Measured at baseline.
This trial requires 130 total participants across 1 different treatment groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Symptoms of prostate cancer can be eliminated with treatment. There is, however, no 100% cure. In addition to treatments discussed in this paper, and the treatment of secondary symptoms such as bone metastases, adjuvant radiation therapy, and androgen ablation, an open approach may be an alternative option, especially in cases where a definitive complete cure is a goal.
Prostate cancer is treated with a variety of treatments, including radical cryo-therapy, surgery, chemotherapy, external beam radiation therapy, hormonal therapies, intraoperative radiation therapy (TOMS), or a combination.
If you were asked to categorize all prostate cancer in the US as either organ-confined, asymptomatic, or advanced prostate cancer, you would get very different answers to this question. Some would say all of these different types of disease exist, but are not true prostate cancer. You would probably say prostate cancer is any one of those categories or none. Most physicians who are experienced with prostate cancer would say there are three, not one, categories of prostate cancer: organ-confined, advanced, and metastatic. If you asked them what is an organ-confined or advanced or metastatic prostate cancer, they would all say what constitutes an organ-confined or advanced or metastatic prostate cancer is somewhat subjective.
Around 250,000 men in the United States are diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) each year. It is the second most common cancer in men in the United States. While there is a gender difference in the incidence, there is no gender difference in mortality rates of prostate cancer.
Signs of prostate cancer include loss of bladder control, frequent urination, decreased erection, inability to void, and pain in the back, abdomen or rectum. Urinary tract infection can present with pain in the abdomen, rectal or bladder area. Any one or more of these may be signs of prostate cancer.
Many men will develop benign prostatic hyperplasia (BPH), a process involving the gradual enlargement of the prostate. Prostate cancer is a rare complication, though uncommon, of a BPH. BPH and BPH related cancer development are very common. As a matter of fact, the prevalence of prostate cancer increases with age.\nOn radiologic image, abnormal cells form in tissue, creating cancerous (cancerous) areas. Often over time, the cancerous areas become abnormal and develop into cancer—this is known as Cancer growth.\nAbout most prostate cancers, there is no set cause. In other words when it occurs, it usually appears. The only known cause of prostate cancer is inherited genetic mutation.
The present review of the literature did not support the current recommendations regarding the optimal management of small prostatic adenomas by the AUA in the absence of symptoms, given the fact that the majority of patients with small prostatic adenomas did not present with symptoms and/or the low rate of malignancy in these patients.
In a recent study, findings are consistent with a role for inherited factors in the etiology of prostate cancer-specific mortality, and they suggest that more in-depth investigations into the heterogeneity of familial prostate cancer may contribute to a better understanding of prostate cancer etiology.
We identified 10 therapies associated with other systemic treatments, mostly in high-risk cases. Overall, in the combination chemotherapy combination, overall response rate increased and time to treatment failure decreased with chemotherapy ± radiation vs chemotherapy ± radiation.
The disease seems to progress to more advanced stage (TNM) in men with higher Gleason scores. However, Gleason score does not change the survival rates.
The treatment of prostate cancer does seem to improve the QOL, particularly in the domains of sexual functioning and mobility, for patients for whom the disease is diagnosed at an early, curable or treatable stage.
Results from a recent paper indicate that the use of antiandrogen treatment could lead to significant clinical improvement. Because BPH often is associated with pain and voiding dysfunction, in addition to decreased QOL in men, we advise treatment of both elements. These elements are alleviated by using antiandrogen treatment.